Document is current
Any future updates will be listed below
-
Authors
Carceles-Cordon, Marc
Rodriguez-Bravo, Veronica
Petrylak, Daniel P.
Domingo-Domenech, Josep
- License Information
-
More Information
Article History
Accepted: 3 October 2025
First Online: 10 November 2025
Competing interests
: D.P.P. reports personal fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Merck & Company Inc., Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis, Seattle Genetics and Urogen, and grants from Ada Cap (Advanced Accelerator Applications), Agensys Inc., Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Eisai, Eli Lilly, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis and Seattle Genetics. The other authors declare no competing interests.
